38-year-old Man from Kerala With Hemophilia Undergoes Open Heart Surgery in Chennai

After the seven-hour surgery, doctors claimed that for the first time in the world, a patient with hemophilia had undergone an open-heart surgery.

A 38-year-old patient from Kerala, Binu Nettikardan, who suffered from a rare blood disorder called hemophilia, where the blood does not clot, underwent a complicated open-heart surgery at MIOT International hospital, Chennai.

Two months ago, Binu complained of chest pain while coughing. He was diagnosed with aneurysm; most doctors were hesitant to operate on him as he has hemophilia.

Potential Treatment for Hemophilia
Researchers have discovered a novel treatment for human hemophilia and a broad range of other bleeding problems.

Binu was referred to MIOT International, where, V.V. Bashi, Chairman of Center for Thoracic and Cardiovascular Care, worked with doctors from six different specialties to find a way to operate on him.

Dr. Bashi, said, “The patient came in with a large aneurysm of the ascending aorta, and a leak in the aortic valve. This procedure needs an open heart surgery, but with haemophilia, even the smallest mistake can cause the patient to bleed to death.”

A team of six specialists performed a seven-hour surgery. The aorta was replaced with a permanent Dacron graft made of synthetic material because metal or titanium grafts have to be replaced after 10 to 12 years.

Hemophilia in Animals Corrected by Genome Editing
Scientists have treated the blood clotting disorder hemophilia in mice by using an innovative gene therapy technique called genome editing

“The patient was connected to a heart-lung machine, his heart was stopped, and the ascending aorta replaced with a synthetic graft. The patient’s valve was repaired and re-implanted into the artificial graft,” said DR. Bashi.

The patient was injected with 2,200 units of anti-hemophilic drug two hours before the surgery. During the surgery, 7,000 units of anti-hemophilic drug were administered every hour to address the issue of blood not clotting.

Trial of Gene Therapy Treatment of Hemophilia B Shows Promise
Four hemophilia B patients in a gene therapy trial using a vector that is being developed to correct the inherited bleeding disorder have shown no toxicity,report investigators.

Doctors claimed this was the first time in the world that a patient with hemophilia had undergone an open-heart surgery. Binu can now lead a normal life and he will be discharged in a day or two.

FDA Starts Review of Biogen�s Therapy for Hemophilia B
The US Food and Drug Administration is currently reviewing Biogen Idec’s application for a fusion protein therapy.

Source-Medindia